Science Corp. raises $230 million as it seeks to bring its brain implants to market

While most of the venture world was angling for AI deals, Max Hudak — co-founder and former president of Neuralink — was working on a startup that claimed it was on the cusp of becoming the first brain-computer interface company to bring a product to market.

These allegations have not gone unnoticed. Hodak’s beginning, Science FoundationIt said Wednesday morning that it has raised $230 million in a Series C funding round. A source close to the startup says the round gave Sciences Corp. a post-money valuation of $1.25 billion.

In the short term, Science Corp PrimaIt is a chip said to be smaller than a grain of rice, and when implanted in the eye, works with camera-equipped glasses to restore functional vision to people with advanced macular degeneration.

The startup has not fully developed the technology itself: it bought the assets of PRIMA in 2024 from the French company Pixium Vision, improved it, and completed the experiments started by Pixium.

But science’s clinical findings since then are its own. In trials involving 47 patients across Europe and the United States, 80% of them showed a significant improvement in visual acuity and were able to read letters, numbers and words, the company says.

“To my knowledge, this is the first time that definitive recovery of the ability to read fluently has been shown in blind patients,” Hudak told TechCrunch. interview In December. The startup device has also been created cover From Time magazine.

It is not clear when Prima will be available to patients, but the regulatory pathway is starting to take shape. Sciences Corp has applied for a CE mark for the implant to the European Union, and says it expects to receive approval in mid-2026, after which it will launch the product on the continent. It claims this timeline will make it the first BCI company to have a product on the market.

The company told TechCrunch that Germany is likely to be its first market, as the country has created pathways to grant early access to new medical technologies. The startup said regulatory discussions with the US Food and Drug Administration are “ongoing” in the United States.

Science Corp. It is also expanding its PRIMA pilot program to include Stargardt’s disease and retinitis pigmentosa, two inherited retinal diseases that are the leading causes of vision loss in young people.

The new capital will be used to fund the commercialization of PRIMA, as well as to support the startup’s broader research portfolio. This includes a Hybrid bio-neural interface A program that involves growing neurons engineered from stem cells onto a waffle-like device placed on the surface of the brain that forms biological connections with existing neural circuits.

There is also a new business line within Science called vessel: A platform for storing organs that aims to develop them in a small way perfusion The technology is such that organs can be flown on commercial flights or maintained by patients at home, rather than in ICU wards.

Investors in the Series C include a mix of new and previous backers, including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, and Quiet Capital. IQT, a non-profit investment firm focused on solutions that can be used by government organizations such as the FBI and CIA, also invested.

This brings the total funding for Science Corp. To 490 million dollars. The startup currently employs 150 people.